

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Barrett *et al.* Confirmation No.: 6905  
Serial No.: 10/510,469 Filing Date: October 7, 2004  
Patent No.: 7,402,606 B2 Issue Date: July 22, 2008  
Title: DERIVATIVES OF 1-(OXOAMINOACETYL)PENTYLCARBAMATE AS  
CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS

---

Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR §1.322 AND §1.323**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322 and §1.323.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge the fee under §1.20(a) (\$100) to Deposit Account No. 07-1392.

Respectfully submitted,

  
Kathryn L. Coulter  
Attorney for Patentee  
Registration No. 45,889

Date: 6/8/2009  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,402,606  
APPLICATION NO.: 10/510,469  
ISSUE DATE : July 22, 2008  
INVENTOR(S) : Barrett et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page:

Please correct the first inventor's residence as follows:

(75) Inventors: -- David Gene Barrett, Norderstedt (DE); --

Please correct the first sentence of the Abstract as follows:

(57) ABSTRACT

-- Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim 1, which are useful as cathepsin K inhibitors are described herein. --

In the Claims:

Claim 2 (Column 122, Line 22) should read as follows:

-- A' is the group defined by  $(Q^4)_p-(Q^3)_n-(Q^2)_m$ , wherein --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GlaxoSmithKline  
Corporate Intellectual Property - MAI-B482  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7,402,606  
APPLICATION NO.: 10/510,469  
ISSUE DATE : July 22, 2008  
INVENTOR(S) : Barrett et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 43 (Column 130, Lines 10-12) should read as follows:

-- (3S)-1-(1H-indol-2-ylcarbonyl)-4,4-dimethylpyrrolidinyl  
(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentylcarbamate; --

Claim 43 (Column 130, Lines 41-43) should read as follows:

-- 3-thienylmethyl(4S)-3,3-dimethyl-4-[[[(1S)-1-(oxo  
{[(1R)-1-phenylethyl]amino}acetyl)pentyl]  
amino]carbonyl)oxy]-1-pyrrolidinecarboxylate; --

Claim 43 (Column 131, Lines 46-48) should read as follows:

-- (3S)-1-[(benzylamino)carbonyl-4,4-dimethylpyrrolidinyl  
(1S)-1-(oxo{[(1R)-1-phenylethyl]amino}acetyl)pentyl-  
carbamate; --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GlaxoSmithKline  
Corporate Intellectual Property - MAI-B482  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.